An interventional study of Multimodal prehabilitation in Non Small Cell Lung Cancer, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain — 160 open to participants now, 333 under way, 112 of them phase 3. Carcinoma, Non-Small-Cell Lung · Spain.
Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, this one is the 649th largest by planned enrollment of the 797 interventional ones that give a count, is one of 58 that started in 2023, is one of 12 with no phase, reaches primary completion later than 125 of the 332 other live ones, and was the 643rd registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →160 of the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Spain, United States, Argentina and 10 more countries
Ages 18+
Hoffmann-La Roche · Sites in Spain, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Spain, United States, Argentina and 9 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Spain, United States, Argentina and 13 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Spain, United States, Canada and 3 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 290 · Phase 2 369 · Phase 3 259 · Phase 4 7
First in 1995; this study’s year is marked. 58 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 188 across the 797 interventional studies, 216 across the 48 observational. Of the 498 that completed or were terminated, 325 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
754 of 851 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.
Hospital Clinic of Barcelona has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
83 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Spain that are under way reach primary completion within a year, 19 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
Add all 83 to your calendar (.ics) → With an account.
Among the 851 studies in Carcinoma, Non-Small-Cell Lung with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neoadjuvant therapy (NAT) with chemoimmunotherapy is currently indicated for patients with locoregional advanced non-small cell lung cancer (NSCLC) prior to resection surgery, but literature has suggested that this is associated with decreased pulmonary function and potentially cardiorespiratory fitness, leading to increased risk of postoperative complications. In this study, we aimed to: 1) compare the effects of NAT on cardiorespiratory fitness (VO2peak) and lung function (DLCO, FEV1 and FVC) in patients with locoregional lung cancer undergoing prehabilitation before lung resection surgery.
Secondary objectives included:
In order to achieve this, we will conduct a prospective study including all patients with NSCLC scheduled for NAT (chemoimmunotherapy or chemotherapy alone) across four different hospitals in Spain and France. Patients will be identified from the multidisciplinary tumour board and will be subsequently referred to the oncologist consultation. After this, one of the members of the researchers will contact the patient and explain the purpose of the study. Those who are willing to participate, will be scheduled to undergo a CardioPulmonary Exercise Test (CPET) in addition to standard lung function tests (spirometry, diffusion capacity of carbon monoxide). After that, patients will be invited to participate in a multimodal prehabilitation program including supervised exercise training, home-based inspiratory muscle training, nutritional optimization and psychological support. Patients who refuse participation in the program due to logistic reasons, will be asked to serve as controls. In addition, we will also use data from a historical cohort including patients treated with chemoimmunotherapy prior to the implementation of the study as controls.
Patients will be assessed at baseline, after NAT and post-surgery (at hospital discharge).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will attend a supervised multimodal prehabilitation programme
Behavioral: Multimodal prehabilitation
Patients declining participation in the prehabilitation program will serve as controls and will receive standard recommendations to increase or maintain their physical activity levels and fitness during the neoadjuvant therapy
The multimodal prehabilitation programme will consist of 1) twice weekly, supervised exercise training at the hospital gym for approximately 12-16 weeks; 2) nutritional consultation and diet optimization and supplementation if needed; 3) individual or group-based psychological support.
Changes in cardiorespiratory fitness assessed with a cardiopulmonary exercise test
Differences in maximum oxygen consumption (VO2pic) pre to post neoadjvuant therapy during an incremental, symptom-limited test
Time frame: 2 weeks post-neoadjuvant therapy
Changes in diffusion capacity of carbon monoxide (DLCO)
Differences in diffusion capacity of carbon monoxide pre to post-neoadjuvant therapy
Time frame: 2 weeks post-neoadjuvant therapy
Changes in submaximal cardiorespiratory fitness assessed with a cardiopulmonary exercise test
Differences in oxygen consumption at the anaerobic threshold (VO2AT) pre to post-neoadjuvant therapy during an incremental, symptom-limited test
Time frame: 2 weeks post-neoadjuvant therapy
Changes in ventilatory efficiency (VE/VCO2 slope) assessed during a cardiopulmonary exercise test
Changes in ventilatory efficiency (VE/VCO2 slope) pre to post-neoadjuvant therapy
Time frame: 2 weeks post-neoadjuvant therapy
Changes in pulmonary function (FEV1)
Differences observed in the maximum volume achieved during the first second (FEV1) of a forced spirometry test, pre to post-neoadjuvant therapy
Time frame: 2 weeks post-neoadjuvant therapy
Changes in pulmonary function (FVC)
Differences observed in the forced ventilatory capacity (FVC) of a forced spirometry test, pre to post-neoadjuvant therapy
Time frame: 2 weeks post-neoadjuvant therapy
Feasibility (recruitment rate ) of multimodal prehabilitation
Feasibility of the multimodal prehabilitation programme assessed by the recruitment rate (number of patients attending prehabilitation versus number of eligible patients)
Time frame: 1 week before surgery
Feasibility (completion rate) of multimodal prehabilitation
Feasibility of the multimodal prehabilitation programme assessed by the completion rate (number of completers among those who accepted to participate in the programme)
Time frame: 1 week before surgery
Adherence
Number of completed exercise sessions in the prehabilitation cohort versus number of scheduled sessions
Time frame: 1 week before surgery
Adverse events
Number of adverse events registered during the exercise training sessions
Time frame: 1 week before surgery
Postoperative Complications
Number and severity of postoperative complications will be assessed by reviewing medical records and calculating the Comprehensive Complication Index (CCI) according to the Clavien-Dindo Classification.
Time frame: within 30 days of hospital discharge
30-Day readmissions, re-interventions and emergency room visits
Readmissions, surgical re-interventions and emergency room visits post-discharge and during the first 30 days will be recorded by reviewing medical records
Time frame: 30 days after surgery
Chemoimmunotherapy completion rates
Chemoimmunotherapy complete dosage, treatment delays and treatment withdrawal rates will be calculated and compared in both groups
Time frame: 1 week post-neoadjuvant therapy
Post-surgery functional capacity
Functional capacity assessed with the 1 min Sit-to-Stand Test which consist of counting the number of times the patient can stand up and sit back onto a chair without arm support during one minute.
Time frame: Same day as dicharge from hospital
Post-NAT functional capacity
Functional capacity assessed with the 1 min Sit-to-Stand Test which consist of counting the number of times the patient can stand up and sit back onto a chair without arm support during one minute.
Time frame: 2 weeks post-neoadjuvant therapy
Post-NAT mood
Anxiety and depression symptoms will be assessed with a self-administer questionnaire, the Hospital Anxiety and Depression Scale
Time frame: 2 weeks post-neoadjuvant therapy
Post-NAT self-reported physical activity
Self-reported physical activity levels will be measured using a validated questionnaire, the Yale Physical Activity Survey
Time frame: 2 weeks post-neoadjuvant therapy
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Feb 2027, 43 months after the start.
Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 43 months is below that.
Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Hospital Clinic of Barcelona →